Skip to content
10-K

Annual Report

Viridian Therapeutics, Inc.\DE VRDN

0001590750-26-000007

← back to feed
Filed
Feb 26, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Feb 20, 2026 102.21M sh
Capex FY 2025 · Dec 31, 2025 $495K
Capex FY 2025 · Dec 31, 2024 $511K
Capex FY 2025 · Dec 31, 2023 $898K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$276.39M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$232.32M
Operating Cash Flow FY 2025 · Dec 31, 2023 −$184.17M
Stockholders Equity FY 2025 · Dec 31, 2025 $722.17M
Stockholders Equity FY 2025 · Dec 31, 2024 $671.64M
Stockholders Equity FY 2025 · Dec 31, 2023 $442.02M
Stockholders Equity FY 2025 · Dec 31, 2022 $395.06M
Current Liabilities FY 2025 · Dec 31, 2025 $70.7M
Current Liabilities FY 2025 · Dec 31, 2024 $47.87M
Total Liabilities FY 2025 · Dec 31, 2025 $177.25M
Total Liabilities FY 2025 · Dec 31, 2024 $70.76M
Current Assets FY 2025 · Dec 31, 2025 $894.23M
Current Assets FY 2025 · Dec 31, 2024 $738.46M
Total Assets FY 2025 · Dec 31, 2025 $899.42M
Total Assets FY 2025 · Dec 31, 2024 $742.4M
Sga Expense FY 2025 · Dec 31, 2025 $95.32M
Sga Expense FY 2025 · Dec 31, 2024 $61.08M
Sga Expense FY 2025 · Dec 31, 2023 $95M
Net Income FY 2025 · Dec 31, 2025 −$342.6M
Net Income FY 2025 · Dec 31, 2024 −$269.95M
Net Income FY 2025 · Dec 31, 2023 −$237.73M
Operating Income FY 2025 · Dec 31, 2025 −$363.4M
Operating Income FY 2025 · Dec 31, 2024 −$299.04M
Operating Income FY 2025 · Dec 31, 2023 −$254.45M